| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/17/2023 | — | Barclays | Upgrades | Equal-Weight → Overweight | |
| 07/26/2023 | 21.23% | Citigroup | $40 → $42 | Maintains | Buy |
| 07/14/2023 | 15.46% | Capital One | → $40 | Initiates Coverage On | → Overweight |
| 06/28/2023 | 15.46% | Citigroup | → $40 | Reiterates | Buy → Buy |
| 04/05/2023 | 15.46% | Citigroup | $41 → $40 | Maintains | Buy |
| 11/02/2022 | -7.63% | Goldman Sachs | $21 → $32 | Maintains | Neutral |
| 11/01/2022 | -1.86% | Citigroup | $30 → $34 | Maintains | Buy |
| 10/06/2022 | -19.18% | Barclays | $38 → $28 | Downgrades | Overweight → Equal-Weight |
| 08/25/2022 | -7.63% | Benchmark | → $32 | Initiates Coverage On | → Buy |
| 07/15/2022 | -36.5% | B of A Securities | → $22 | Upgrades | Neutral → Buy |
| 07/13/2022 | -39.39% | Goldman Sachs | $26 → $21 | Maintains | Neutral |
| 05/02/2022 | 9.68% | Barclays | $33 → $38 | Maintains | Overweight |
| 04/11/2022 | -13.41% | Piper Sandler | $28 → $30 | Upgrades | Neutral → Overweight |
| 03/11/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 02/22/2022 | -30.73% | Goldman Sachs | → $24 | Upgrades | Sell → Neutral |
| 11/01/2021 | 1.02% | Barclays | $29 → $35 | Maintains | Overweight |
| 09/17/2021 | -36.5% | Goldman Sachs | → $22 | Initiates Coverage On | → Sell |
| 02/25/2021 | -37.94% | Credit Suisse | $18.5 → $21.5 | Maintains | Outperform |
| 12/22/2020 | -39.39% | Goldman Sachs | → $21 | Initiates Coverage On | → Buy |
| 10/30/2020 | -56.7% | Credit Suisse | $13 → $15 | Maintains | Outperform |
| 10/07/2020 | -66.52% | Piper Sandler | $12.6 → $11.6 | Maintains | Neutral |
| 09/16/2020 | -65.36% | Scotiabank | → $12 | Initiates Coverage On | → Sector Outperform |
| 09/11/2020 | -62.48% | Credit Suisse | → $13 | Initiates Coverage On | → Outperform |
| 09/08/2020 | -53.82% | Evercore ISI Group | → $16 | Upgrades | In-Line → Outperform |
| 08/10/2020 | -63.63% | Piper Sandler | $10.5 → $12.6 | Maintains | Neutral |
| 06/26/2020 | -56.7% | Stifel | → $15 | Initiates Coverage On | → Buy |
| 06/22/2020 | -65.36% | B of A Securities | → $12 | Initiates Coverage On | → Buy |
What is the target price for ChampionX (CHX)?
The latest price target for ChampionX (NASDAQ: CHX) was reported by Barclays on October 17, 2023. The analyst firm set a price target for $0.00 expecting CHX to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ChampionX (CHX)?
The latest analyst rating for ChampionX (NASDAQ: CHX) was provided by Barclays, and ChampionX upgraded their overweight rating.
When is the next analyst rating going to be posted or updated for ChampionX (CHX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ChampionX, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ChampionX was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.
Is the Analyst Rating ChampionX (CHX) correct?
While ratings are subjective and will change, the latest ChampionX (CHX) rating was a upgraded with a price target of $0.00 to $0.00. The current price ChampionX (CHX) is trading at is $34.65, which is out of the analyst's predicted range.